The incidence of metastatic hormone-sensitive prostate cancer (mHSPC) has significantly increased in recent years, in part due to advancements in imaging technology. Men with metastatic prostate cancer who have not received prior treatment with androgen deprivation therapy (ADT) or who are still sensitive to ADT and do not have castration-resistant cancer are defined as having mHSPC, a lethal disease with a reported median survival of less than 5 years. ADT has long been the standard of care for patients with mHSPC. However, the development of innovative therapeutic options in recent years has significantly improved survival.
Are you familiar with the evolving treatment paradigm for managing patients with mHSPC? Test your knowledge with this quick quiz.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Bradley Schwartz, Daniel S. Schwartz. Fast Five Quiz: Metastatic Hormone-Sensitive Prostate Cancer Treatment - Medscape - Jun 27, 2022.
Comments